摘要
目的:本研究通过观察应用岩舒注射液对肝动脉插管化疗栓塞术(TACE)后患者综合指标及术后副反应的前后对比,来探讨岩舒注射液对TACE的辅助作用。方法:选取原发性肝癌住院患者60名,随机分为治疗组30名,对照组30名。均行TACE,对照组保肝、支持对症及化疗介入;治疗组给予保肝、支持对症及化疗介入,另外术前给予岩舒注射液40ml静脉输注,2周为1疗程。观察两组疗效、临床症状及毒副反应。结果:治疗组有效率为16.7%,对照组为10%,两组比较无显著性差异(P>0.05)。临床症状对肝功能有较好的保护作用,治疗组肝功能治疗后进级者占10%,而对照组占30%,两组比较有显著性差异(P<0.05)。结论:肝癌介入治疗同时联合应用岩舒注射液,可以保护肝功能,改善患者临床症状,特别是消除肝区疼痛,提高免疫力及减少毒副作用。
OBJECTIVE： To study the adjunctive effect of yanshu on TACA （hepatic artery catheterization chemoembolization） by monitoring the comprehensive indexes and the postoperative side reactions in patients undergoing TACA. METHODS： A total of 60 patients with primary hepatic carcinoma （PHC） were enrolled and randomized to treatment group （30 cases） and control group （30 cases）. Both group undergone TACE. Both the control group and the treatment group were treated with liver protectants, symptomatic supporting treatment and chemotherapy; while the treatment group was treated additionally with yanshu injection （40ml, 1 course of treatment = 2weeks） before operation by intravenous infusion. The main outcome measures for the 2 groups were curative effects, clinical symptoms and toxic reactions. RESULTS： The effective rates for the treatment group and the control group were 16.7% and 10% respectively, and there was no significant difference between 2 groups （ P 〉 0.05 ）. However, there were significant differences in clinical symptoms between 2 groups （P 〈 0.05）. The treatment group showed a better liver protective effect, with only 10% advanced in grade in liver function after treatment while 30% for control group, and there were significant differences between 2 groups （P 〈 0.05 ）. CONCLUSION： Interventional therapy in combination of yanshu injection can protect liver function, ameliorate clinical symptoms, esp. in eliminating hepatic region pain, and improve immunity and reduce toxic reactions.
出处
《中国医院用药评价与分析》
2006年第6期374-375,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
原发性肝癌
岩舒
TACE
primary hepatic carcinoma （PHC）
yanshu
TACE
